Development
Biodesix, Inc.
BDSX
$0.3029
$0.02117.49%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 28.46% | 22.88% | 33.24% | 26.51% | -29.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.46% | 22.88% | 33.24% | 26.51% | -29.89% |
| Cost of Revenue | -8.08% | -2.99% | 7.37% | -9.31% | -53.62% |
| Gross Profit | 49.96% | 38.22% | 50.33% | 59.92% | 0.29% |
| SG&A Expenses | 9.64% | 16.04% | 18.45% | 24.28% | 21.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.88% | 9.80% | 13.89% | 14.66% | -5.44% |
| Operating Income | 18.23% | -0.10% | -1.98% | -6.89% | -28.46% |
| Income Before Tax | 20.32% | -8.48% | -17.59% | -32.40% | -51.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.32% | -8.48% | -17.59% | -32.40% | -51.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.32% | -8.48% | -17.59% | -32.40% | -51.64% |
| EBIT | 18.23% | -0.10% | -1.98% | -6.89% | -28.46% |
| EBITDA | 19.06% | -0.79% | -2.34% | -7.10% | -29.80% |
| EPS Basic | 59.45% | 48.12% | 39.04% | 26.45% | -1.35% |
| Normalized Basic EPS | 55.34% | 49.70% | 43.86% | 37.31% | 9.21% |
| EPS Diluted | 59.45% | 48.12% | 39.04% | 26.45% | -1.35% |
| Normalized Diluted EPS | 55.34% | 49.70% | 43.86% | 37.31% | 9.21% |
| Average Basic Shares Outstanding | 94.77% | 113.17% | 102.93% | 88.96% | 54.01% |
| Average Diluted Shares Outstanding | 94.77% | 113.17% | 102.93% | 88.96% | 54.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |